Skip to main content
Premium Trial:

Request an Annual Quote

Paired Ends: Kip Miller, Dale Levitzke

Premium

Kip Miller has been elected to the board of directors at Firefly BioWorks. Previously, he served as president of genetic systems at Life Technologies, where he was responsible for the Applied Biosystems DNA sequencing business and development of applications in forensic and HLA diagnostics. During his term at Life Tech, he also served as senior vice president of the Biodiscovery and Enabling Technologies Division in Life Tech's Invitrogen business. Prior to joining Life Tech, he held multiple roles at BD Biosciences.


Dale Levitzke has been appointed to vice president of global sales for life sciences at NanoString Technologies. Levitzke joins the company from Illumina, where he was senior director and global sales manager for the company's PCR division.

Previously, he was head of global sales for Helixis, general manager of Corbett Robotics, and core facility manager at the University of Newcastle's Analytical and Biomolecular Research Facility. He holds a BS in molecular biology from La Trobe University Melbourne.

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.